Doses Of Sulfadoxine-pyrimethamine Research Articles

Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine-pyrimethamine.

With the knowledge that an efficacious antimalarial administered to pregnant women would markedly reduce placental malaria and its associated risk of low birth weight (LBW), investigations were conducted to identify an antimalarial regimen practical for nationwide implementation through the antenatal clinic (ANC) system. Maternal practices, including ANC utilization and malaria treatment and prevention during pregnancy were evaluated as part of a national malaria knowledge, attitudes, and practices survey. A second study was conducted to evaluate the efficacy and cost of selected alternative antimalarial regimens. Women in their first or second pregnancy were placed on chloroquine (CQ) treatment (25 mg/kg) followed by weekly CQ (300 mg) (CQ/CQ); sulfadoxine-pyrimethamine (SP) treatment followed by CQ (300 mg weekly) (SP/CQ); or SP treatment during the second trimester and repeated at the beginning of the third trimester (SP/SP). With 87% of women attending ANC two or more times during pregnancy, most pregnant women in Malawi could be reached with an antimalarial intervention. Among 159 women in their first or second pregnancy receiving CQ/CQ, SP/CQ, and SP/SP, placental malaria parasitemia rates were 32%, 26%, and 9%, respectively (P = 0.006, by chi-square test). The SP/SP regimen was also markedly more cost-effective in preventing infant deaths, costing $75 per infant death prevented, compared with $481 for SP/CQ and $542 for CQ/CQ. These investigations suggest that a regimen consisting of two treatment doses of SP during pregnancy is an efficacious and cost-effective intervention to prevent placental malaria, and LBW-associated mortality, that can be delivered to pregnant women through ANCs in settings similar to those found in rural Malawi.

Comparison of intramuscular sulfadoxine-pyrimethamine and intramuscular quinine for the treatment of falciparum malaria in children

The efficacy of intramuscular (i.m.) sulfadoxine-pyrimethamine (sulfadoxine 25 mg/kg plus pyrimethamine 1·25 mg/kg in a single dose; n = 48) was compared with that of i.m. quinine (10 mg/kg 8-hourly for at least 3 d followed by oral quinine to complete 7 d; n = 54) in children with severe malaria without life-threatening complications in Maputo Central Hospital, Mozambique, in 1989. Mean parasite clearance time and mean fever clearance time were 55·4 h and 48·1 h, respectively, in the sulfadozine-pyrimethamine group, and 60·7 h and 54 h in the quinine group. Seven cases in the sulfadoxine-pyrimethamine group were RII/RIII resistant compared with none in the quinine group, but parasite reduction during the first 48 h was no slower in the resistant cases than in the 7 poorest responders to quinine. Blood sugar levels were slightly, but not significantly, lower in the quinine group. On day 7, leucocyte counts were significantly lower in the sulfadoxine-pyrimethamine group, but within the normal range. It is concluded that a single dose of sulfadoxine-pyrimethamine may be useful for the treatment of complicated malaria at health care units without facilities for admission, or if transferral is necessary after start of treatment.

Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro

88 asymptomatic Tanzanian schoolchildren with Plasmodium falciparum parasitaemia were given all, half or quarter of the recommended standard therapeutic dose of sulfadoxine-pyrimethamine (Fansidar ®). All children cleared the parasites by day 3 and all remained negative during 28–42 days of follow-up. All 32 successful in vitro micro-tests showed full sensitivity. High performance liquid Chromatographic methods were applied for drug determinations. Using 100 μ1 capillary blood dried on filter paper for sulfadoxine determination the interindividual variation during follow-up of the standard dose group was 2–4 fold and the median half life was 8·9 d. Sulfadoxine concentrations in the half and quarter dose groups were roughly proportional to those in the standard dose group. The median whole blood to plasma concentration ratio for sulfadoxine was 0·72 and the correlation coefficient 0·95. There was only a weak correlation ( r = 0·46) between plasma concentrations of sulfadoxine and pyrimethamine. The uniform efficacy of sulfadoxine-pyrimethamine in vivo, even when reduced doses were used, makes this combination a good alternative for treatment of P. falciparum in Tanzania.

The treatment of malaria.

At least four doses of quinine followed by a single dose of mefloquine or by a single dose of sulfadoxine-pyrimethamine are two highly effective regimens for chloroquine-resistant falciparum malaria. Mefloquine alone is valuable in ambulant patients. Chloroquine-sensitive falciparum malaria can be treated with a course of chloroquine. Vivax and all other types of malaria should be treated with sequential chloroquine and primaquine. Quinine, by intravenous infusion, is the most effective drug for severe falciparum malaria. The optimum intravenous dose varies between 5 mg/kg and 10 mg/kg administered over four hours. Intravenous or oral quinine should be administered about every 12 hours and the total daily dose of quinine should rarely exceed 20 mg/kg. Intravenous fluid input should be controlled in falciparum malaria to prevent pulmonary oedema. Established renal failure is best treated by dialysis. The value of adrenocortical steroids for falciparum coma has not been established. Fresh blood transfusion may be helpful in small doses for severe anaemia and to replace clotting factors. Anticoagulants, such as heparin, should not be used in falciparum malaria.

Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine.

Quinine (at least four doses given at intervals of eight to 12 hours) followed by a single dose of sulfadoxine-pyrimethamine (Fansidar) is the most effective treatment of chloroquine-resistant falciparum malaria. This regimen cured 96% of patients (302 out of 314) with an average initial parasite count of 90 X 10-9/1.